查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595561

Pregabalin市場：按劑型、藥物類別、應用、最終用戶、通路 - 全球預測 2025-2030

Pregabalin Market by Dosage Forms (Extended Release, Oral Capsule, Oral Solution), Drug Class (Anticonvulsants, Fibromyalgia Agents), Application, End-Users, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年Pregabalin市場價值為11.2億美元，預計到2024年將達到12億美元，複合年成長率為7.74%，預計到2030年將達到18.9億美元。

Pregabalin是一種主要用於治療神經痛、癲癇和整體焦慮症的藥物，由於其廣泛的治療用途，在全球醫藥市場中佔據重要佔有率。對Pregabalin的需求源於其在治療神經病變疼痛、纖維肌痛和癲癇相關疾病方面的有效性，從而在醫療保健領域產生了強勁的需求。最終用途主要包括醫院、診所和家庭護理機構，因為這些疾病的發生率在全球範圍內不斷增加。加強Pregabalin市場的主要影響因素包括慢性疼痛疾病盛行率的上升、易受神經損傷的老年人口的增加以及對神經病變疼痛的認知和診斷的提高。此外，正在進行的研究和開發旨在擴大治療適應症並提高藥物療效，從而提供新的成長機會。最近的潛在機會包括開出副作用較少的替代藥物以及修改當前劑量以提高安全性和有效性。為了充分利用這些機會，製造商可能會專注於創新藥物輸送系統和學名藥，以開拓開拓的市場。然而，這些成長前景受到諸如嚴格的法律規範、濫用導致依賴性問題的可能性以及影響患者獲取的高藥物成本等挑戰的限制。替代療法和專利到期帶來的激烈競爭也構成了市場威脅。然而，潛在的創新和研究領域正在出現，包括開發基於奈米技術的製劑以及考慮與其他藥物組合以增強治療效果。此外，市場相關人員可能會追求基於價值的定價策略，以在不影響盈利的情況下提高可及性。該市場競爭激烈且有望成長，需要策略聯盟和持續的研發投資，以解決現有限制並有效開拓新的市場前景。

主要市場統計
基準年[2023] 11.2億美元
預測年份 [2024] 12億美元
預測年份 [2030] 18.9億美元
複合年成長率（%） 7.74%

市場動態：揭示快速發展的Pregabalin市場的關鍵市場洞察

供需的動態交互作用正在改變Pregabalin市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 癲癇和焦慮症病例增加
    • 政府積極努力提高對焦慮症的認知
    • 患有神經病變疼痛的老年人口不斷增加
  • 市場限制因素
    • 替代品的存在與缺乏意識
  • 市場機會
    • 學名藥核准增加
    • Pregabalin的進展與產品增強
  • 市場挑戰
    • 不良健康影響和產品召回

波特的五力：駕馭Pregabalin市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解Pregabalin市場的外部影響

外部宏觀環境因素在塑造Pregabalin市場的業績動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解Pregabalin市場的競爭狀況

對Pregabalin市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣Pregabalin市場供應商績效評估

FPNV定位矩陣是評估Pregabalin市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製Pregabalin市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，Pregabalin市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癲癇和焦慮症增加
      • 政府為提高對不安全問題的認知而採取的有利舉措
      • 患有神經病變疼痛的老年人口不斷增加
    • 抑制因素
      • 替代品的存在與缺乏意識
    • 機會
      • 學名藥核准增加
      • Pregabalin的進展與產品增強
    • 任務
      • 不良健康影響和產品召回
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章Pregabalin市場按劑型

  • 延長釋放
  • 口服膠囊
  • 口服液
  • 口服錠劑

第7章依藥物類別分類的Pregabalin市場

  • 抗驚厥藥
  • 纖維肌痛治療藥物

第8章Pregabalin市場：依應用分類

  • 焦慮症
  • 癲癇
  • 神經病變疼痛

第 9 章Pregabalin市場：依最終用戶分類

  • 居家護理
  • 醫院
  • 調查機構
  • 專科診所

第10章Pregabalin市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 美洲Pregabalin市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區Pregabalin市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲Pregabalin市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Almelo Private Limited
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • BAL Pharma Ltd.
  • Cipla Limited
  • Dongbang FTL
  • Genesis Biotec Inc.
  • Hikal Ltd.
  • Lupin Limited
  • Medley Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-957C47F916B3

The Pregabalin Market was valued at USD 1.12 billion in 2023, expected to reach USD 1.20 billion in 2024, and is projected to grow at a CAGR of 7.74%, to USD 1.89 billion by 2030.

Pregabalin, a medication primarily used to treat nerve pain, seizures, and generalized anxiety disorder, represents a significant segment of the global pharmaceutical market due to its broad therapeutic applications. The necessity for pregabalin arises from its efficacy in managing conditions associated with neuropathic pain, fibromyalgia, and epilepsy, creating a robust demand in the healthcare sector. End-use scope primarily includes hospitals, clinics, and homecare settings, tapping into the increasing incidence of such conditions worldwide. Key influencing factors bolstering the pregabalin market include the rising prevalence of chronic pain disorders, expanding geriatric population susceptible to nerve damage, and increasing awareness and diagnosis of neuropathic pain. Moreover, ongoing research and development are aimed at expanding therapeutic indications and improving drug efficacy, presenting new growth opportunities. Recent potential opportunities include formulating pregabalin alternatives with fewer side effects and modifying current dosages to enhance safety and efficacy. To maximize these opportunities, manufacturers could focus on innovative drug delivery systems and generic versions to tap into untapped markets. However, these growth prospects are tempered by challenges such as stringent regulatory frameworks, potential misuse leading to dependency concerns, and the high cost of medication, impacting patient access. Fierce competition from alternative therapies and the expiration of patents further pose market threats. Nonetheless, areas for potential innovation and research are emerging in developing nanotechnology-based formulations and exploring combinations with other drugs to enhance therapeutic outcomes. Additionally, market players could pursue value-based pricing strategies to enhance accessibility without compromising profitability. The nature of the pregabalin market is highly competitive yet poised for growth, with a need for strategic collaborations and continued investment in R&D to address existing limitations and capitalize on new market prospects efficiently.

KEY MARKET STATISTICS
Base Year [2023] USD 1.12 billion
Estimated Year [2024] USD 1.20 billion
Forecast Year [2030] USD 1.89 billion
CAGR (%) 7.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pregabalin Market

The Pregabalin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing cases of epilepsy and anxiety disorders
    • Favorable government initiatives for raising awareness for anxiety issues
    • Rising geriartic population with neuropathic pain
  • Market Restraints
    • Presence of substitutes and lack of awareness
  • Market Opportunities
    • Rising approvals of generic versions of the medicine
    • Advancements and product enhancements for pregabalin
  • Market Challenges
    • Adverse effects on health and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Pregabalin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pregabalin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pregabalin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pregabalin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pregabalin Market

A detailed market share analysis in the Pregabalin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pregabalin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pregabalin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pregabalin Market

A strategic analysis of the Pregabalin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pregabalin Market, highlighting leading vendors and their innovative profiles. These include Almelo Private Limited, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, BAL Pharma Ltd., Cipla Limited, Dongbang FTL, Genesis Biotec Inc., Hikal Ltd., Lupin Limited, Medley Pharmaceuticals Limited, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Pregabalin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage Forms, market is studied across Extended Release, Oral Capsule, Oral Solution, and Oral Tablet.
  • Based on Drug Class, market is studied across Anticonvulsants and Fibromyalgia Agents.
  • Based on Application, market is studied across Anxiety Disorder, Epilepsy, and Neuropathic Pain.
  • Based on End-Users, market is studied across Homecare, Hospitals, Research institute, and Specialty Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of epilepsy and anxiety disorders
      • 5.1.1.2. Favorable government initiatives for raising awareness for anxiety issues
      • 5.1.1.3. Rising geriartic population with neuropathic pain
    • 5.1.2. Restraints
      • 5.1.2.1. Presence of substitutes and lack of awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising approvals of generic versions of the medicine
      • 5.1.3.2. Advancements and product enhancements for pregabalin
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects on health and product recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pregabalin Market, by Dosage Forms

  • 6.1. Introduction
  • 6.2. Extended Release
  • 6.3. Oral Capsule
  • 6.4. Oral Solution
  • 6.5. Oral Tablet

7. Pregabalin Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anticonvulsants
  • 7.3. Fibromyalgia Agents

8. Pregabalin Market, by Application

  • 8.1. Introduction
  • 8.2. Anxiety Disorder
  • 8.3. Epilepsy
  • 8.4. Neuropathic Pain

9. Pregabalin Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Research institute
  • 9.5. Specialty Clinics

10. Pregabalin Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Americas Pregabalin Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Pregabalin Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Pregabalin Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Almelo Private Limited
  • 2. Amneal Pharmaceuticals LLC
  • 3. Aurobindo Pharma Limited
  • 4. BAL Pharma Ltd.
  • 5. Cipla Limited
  • 6. Dongbang FTL
  • 7. Genesis Biotec Inc.
  • 8. Hikal Ltd.
  • 9. Lupin Limited
  • 10. Medley Pharmaceuticals Limited
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Torrent Pharmaceuticals Ltd.
  • 15. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. PREGABALIN MARKET RESEARCH PROCESS
  • FIGURE 2. PREGABALIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREGABALIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PREGABALIN MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PREGABALIN MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. PREGABALIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. PREGABALIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREGABALIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREGABALIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREGABALIN MARKET DYNAMICS
  • TABLE 7. GLOBAL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREGABALIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREGABALIN MARKET SIZE, BY ORAL CAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREGABALIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREGABALIN MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREGABALIN MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREGABALIN MARKET SIZE, BY FIBROMYALGIA AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PREGABALIN MARKET SIZE, BY ANXIETY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREGABALIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PREGABALIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PREGABALIN MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PREGABALIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PREGABALIN MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PREGABALIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PREGABALIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PREGABALIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PREGABALIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PREGABALIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PREGABALIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PREGABALIN MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PREGABALIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. PREGABALIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. PREGABALIN MARKET, FPNV POSITIONING MATRIX, 2023